Treatment of post-traumatic stress disorder

A technique for post-traumatic stress and disorders, applied in the field of inhibiting dopamine beta-hydroxylase, evaluating signs of post-traumatic stress disorder, and improving patient resilience

Inactive Publication Date: 2011-01-19
生物系治疗公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Difficulties with the use of lamotrigine, the need for titration, and the risk of developing Steven Johnson syndrome, life-threatening rash, make it a poor candidate for therapeutic use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of post-traumatic stress disorder
  • Treatment of post-traumatic stress disorder
  • Treatment of post-traumatic stress disorder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0364] A clinical study was conducted to demonstrate the efficacy and tolerability of Compound A in the treatment of post-traumatic stress disorder (PTSD).

[0365] The study design included an 8-week randomized, double-blind, placebo-controlled treatment trial of Compound A for the treatment of PTSD.

[0366] After signing informed consent and meeting inclusion / exclusion criteria, patients were randomized to receive Compound A or placebo for an 8-week period. During the study, the pharmacist kept records of the randomization and confirmed the order of placebo or Compound A (both are similar looking tablets). Patients were evaluated every two weeks for symptoms, side effects, and compliance.

[0367] Depending on the onset of symptoms and side effects, investigators may increase the drug in increments of 20-40 mg, as tolerated, until maximum therapeutic benefit is achieved. Dosing was once daily unless twice daily was better tolerated. Compliance was assessed by pill count ...

Embodiment 2

[0404] A clinical study was conducted to demonstrate the efficacy and tolerability of Compound A in the prevention of PTSD.

[0405] The study design included an open-ended randomized, double-blind, placebo-controlled treatment trial of Compound A for the prevention of PTSD. After signing informed consent and meeting inclusion / exclusion criteria, patients were randomized to receive Compound A versus placebo for an 8-week period. During the study, the pharmacist kept records of the randomization and confirmed the order of placebo or Compound A (both are similar looking tablets). Patients were evaluated every two weeks for symptoms, side effects, and compliance.

[0406] Depending on the onset of symptoms and side effects, investigators may increase the drug in increments of 20-40 mg, as tolerated, until maximum therapeutic benefit is achieved. Dosing was once daily unless twice daily was better tolerated. Compliance was assessed by pill count at weeks 4 and 8.

[0407] Pati...

Embodiment 3

[0445] A clinical study was performed to demonstrate the efficacy and tolerability of Compound A combination therapy in the treatment of PTSD.

[0446] The study design included an 8-week randomized, double-blind, placebo-controlled treatment trial of Compound A for the treatment of PTSD. After signing informed consent and meeting inclusion / exclusion criteria, patients were randomized to receive Compound A or placebo for an 8-week period. Patients also received therapeutically effective doses of prazosin, valproate, carbamazepine or topiramate in combination with compound A or placebo.

[0447] During the study, the pharmacist kept records of the randomization and confirmed the order of placebo or Compound A (both are similar looking tablets). Patients were evaluated every two weeks for symptoms, side effects, and compliance. Depending on the onset of symptoms and side effects, investigators increased the drug in increments of 20-40 mg, as tolerated, until maximum therapeuti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided are methods of treating a patient diagnosed with post-traumatic stress disorder, by administering to the patient a therapeutically effective amount of Compound A. Also provided are methods of improving resilience in a patient by administering a therapeutically effective amount of Compound A. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of Compound A and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the Compound A reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit and priority of U.S. Provisional Patent Application Serial No. 60 / 935,036 "Treatment of Post-Traumatic Stress Disorder," filed July 23, 2007, under 35 U.S.C. § 119(e), the entirety of which is incorporated by reference into this article. field of invention [0003] This document relates generally to methods of treating post-traumatic stress disorder, and more particularly to methods of using Compound A for treating post-traumatic stress disorder, methods of inhibiting dopamine beta-hydroxylase. Also provided are methods of improving the resilience of a patient by administering a therapeutically effective amount of Compound A. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of Compound A, and methods of evaluating at least one of the signs, symptoms, or syndromes of post-traumatic str...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/535
CPCA61K31/535A61K31/4164A61K45/06A61P25/00A61P25/18A61P43/00A61K2300/00
Inventor T·沃伊沃德M·莫兰
Owner 生物系治疗公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap